In conclusion, our study shows that intracranial PD-L1 TPS derived from brain metastasis tissue may inform about outcome, especially intracranial disease progression, and could represent a valuable predictive marker to stratify NSCLC patients with brain metastases for ICI therapy. Here, CD274 is linked to non-small cell lung carcinoma.